Glucagon-like peptide-1, or GLP-1, is a hormone thats made by your small intestine
As their use has expanded dramatically in recent years, questions about long-term safety, including potential cancer risk, have become increasingly important for both patients and clinicians
The rate of non-fatal stroke, non-fatal MI, and hospitalization for HF did not show significant differences ( Other contemporary studies, such as the EXSCEL and FREEDOM trials evaluated the cardiovascular effects of exenatide, a GLP-1 RA ( The REWIND trial investigated the cardiovascular benefits of dulaglutide, a GLP-1 receptor agonist, in a population of 9,901 patients with T2DM aged 50+ and either established CVD or risk factors
It remains in Phase 3 clinical development, and regulatory submissions to the MHRA and EMA have not yet been completed